Dr. Adrian Senderowicz, MD

NPI: 1396935649
Total Payments
$1.5M
2024 Payments
$159,640
Companies
3
Transactions
60

Payment Breakdown by Category

Consulting$1.5M (99.1%)
Travel$11,914 (0.8%)
Other$1,600 (0.1%)
Food & Beverage$206.90 (0.0%)

Payments by Nature

Nature of Payment Amount Transactions Share
Consulting Fee $1.5M 43 99.1%
Travel and Lodging $11,914 13 0.8%
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1,600 1 0.1%
Food and Beverage $206.90 3 0.0%

Top Paying Companies

Company Total Records Latest Year
PUMA BIOTECHNOLOGY, INC. $1.4M 51 $0 (2024)
Blueprint Medicines Corporation $152,625 8 $0 (2023)
Siemens Medical Solutions USA, Inc. $1,600 1 $0 (2023)

Payment History by Year

Year Amount Transactions Top Company
2024 $159,640 5 PUMA BIOTECHNOLOGY, INC. ($159,640)
2023 $318,995 14 Puma Biotechnology, Inc. ($164,770)
2022 $150,788 5 PUMA BIOTECHNOLOGY, INC. ($150,788)
2021 $368,677 5 PUMA BIOTECHNOLOGY, INC. ($368,677)
2020 $288,023 5 Puma Biotechnology, Inc. ($288,023)
2019 $156,109 19 Puma Biotechnology, Inc. ($156,109)
2018 $65,979 7 Puma Biotechnology, Inc. ($65,979)

All Payment Transactions

60 individual payment records from CMS Open Payments — Page 1 of 3

Date Company Product Nature Form Amount Type
10/01/2024 PUMA BIOTECHNOLOGY, INC. Consulting Fee Stock, stock option, or any other ownership interest $89,640.00 General
10/01/2024 PUMA BIOTECHNOLOGY, INC. Consulting Fee Cash or cash equivalent $17,500.00 General
07/02/2024 PUMA BIOTECHNOLOGY, INC. Consulting Fee Cash or cash equivalent $17,500.00 General
04/02/2024 PUMA BIOTECHNOLOGY, INC. Consulting Fee Cash or cash equivalent $17,500.00 General
01/02/2024 PUMA BIOTECHNOLOGY, INC. Consulting Fee Cash or cash equivalent $17,500.00 General
11/17/2023 Blueprint Medicines Corporation Consulting Fee Cash or cash equivalent $24,000.00 General
10/20/2023 Blueprint Medicines Corporation Consulting Fee Cash or cash equivalent $22,500.00 General
10/02/2023 Puma Biotechnology, Inc. Consulting Fee Cash or cash equivalent $17,500.00 General
08/31/2023 Siemens Medical Solutions USA, Inc. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Cash or cash equivalent $1,600.00 General
08/25/2023 Blueprint Medicines Corporation Consulting Fee Cash or cash equivalent $15,000.00 General
08/04/2023 Blueprint Medicines Corporation Consulting Fee Cash or cash equivalent $7,500.00 General
07/28/2023 Blueprint Medicines Corporation Consulting Fee Cash or cash equivalent $30,000.00 General
07/03/2023 Puma Biotechnology, Inc. Consulting Fee Cash or cash equivalent $17,500.00 General
06/30/2023 Blueprint Medicines Corporation Consulting Fee Cash or cash equivalent $15,000.00 General
06/16/2023 Blueprint Medicines Corporation Consulting Fee Cash or cash equivalent $7,500.00 General
06/09/2023 Blueprint Medicines Corporation Consulting Fee Cash or cash equivalent $31,125.00 General
04/03/2023 Puma Biotechnology, Inc. Consulting Fee Cash or cash equivalent $17,500.00 General
01/03/2023 Puma Biotechnology, Inc. Consulting Fee Cash or cash equivalent $17,500.00 General
01/01/2023 Puma Biotechnology, Inc. Consulting Fee Stock, stock option, or any other ownership interest $94,770.00 General
10/01/2022 PUMA BIOTECHNOLOGY, INC. NERLYNX (Drug) Consulting Fee In-kind items and services $17,500.00 General
Category: ONCOLOGY
07/01/2022 PUMA BIOTECHNOLOGY, INC. NERLYNX (Drug) Consulting Fee In-kind items and services $17,500.00 General
Category: ONCOLOGY
04/01/2022 PUMA BIOTECHNOLOGY, INC. NERLYNX (Drug) Consulting Fee In-kind items and services $17,500.00 General
Category: ONCOLOGY
01/01/2022 PUMA BIOTECHNOLOGY, INC. NERLYNX (Drug) Consulting Fee Stock, stock option, or any other ownership interest $80,788.20 General
Category: ONCOLOGY
01/01/2022 PUMA BIOTECHNOLOGY, INC. NERLYNX (Drug) Consulting Fee In-kind items and services $17,500.00 General
Category: ONCOLOGY
10/01/2021 PUMA BIOTECHNOLOGY, INC. NERLYNX (Drug) Consulting Fee Cash or cash equivalent $17,500.00 General
Category: ONCOLOGY

About Dr. Adrian Senderowicz, MD

Dr. Adrian Senderowicz, MD is a Medical Oncology healthcare provider based in Bethesda, Maryland. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/01/2007. The National Provider Identifier (NPI) number assigned to this provider is 1396935649.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Adrian Senderowicz, MD has received a total of $1.5M in payments from pharmaceutical and medical device companies, with $159,640 received in 2024. These payments were reported across 60 transactions from 3 companies. The most common payment nature is "Consulting Fee" ($1.5M).

Practice Information

  • Specialty Medical Oncology
  • Location Bethesda, MD
  • Active Since 08/01/2007
  • Last Updated 08/14/2007
  • Taxonomy Code 207RX0202X
  • Entity Type Individual
  • Practice Solo Practitioner
  • NPI Number 1396935649

Products in Payments

  • NERLYNX (Drug) $807,488
  • Nerlynx (Drug) $222,088

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.

Medical Oncology Doctors in Bethesda